Skip to main content
Premium Trial:

Request an Annual Quote

Xerion Pharmaceuticals Licenses Xoma Ireland Antibody Expression Technology

NEW YORK, Aug. 13 (GenomeWeb News) --  Xerion Pharmaceuticals of Martinsried, Germany, announced today that it has licensed bacterial expression technology developed by Xoma Ireland.

In a statement, Xerion said it will have rights to use Xoma’s antibody expression technology for developing antibody products derived from phage display libraries for itself and its collaborators. The company also has an option to license the production of antibodies under Xoma patents. Xoma will receive license and royalty payments. The two companies also announced a co-development and commercialization option on antibody products generated by Xerion.

Further financial details were not provided.

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.